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Abstract
Background Postmenopausal osteoporosis (PMO) is com-
mon among women over 50 years of age and is associated
with an increased risk of fracture. Bone-targeted agents,
such as denosumab, can reduce fracture risk in patients
with PMO.
Objective The aim was to describe baseline characteristics
and changes in bone mineral density (BMD) T-scores
among women with PMO receiving denosumab in
Bulgaria.
Methods This multicenter chart review included women
with PMO receiving denosumab for C1 year in Bulgaria
(October 2011–August 2013). Participants were required to
have a baseline BMD T-score of B-2.5 standard devia-
tions (SDs) at one or more skeletal sites.
Results Overall, 222 women were included. The mean
(SD) age at denosumab initiation was 64.2 (8.5) years;
26.6% reported a previous osteoporotic fracture and 6.8% a
previous hip fracture. Only half of those reporting a pre-
vious fracture (49.2%) had received prior osteoporosis
therapy. At baseline, mean (SD) BMD T-scores were
lumbar spine -3.2 SD (0.6 SD), total hip -2.3 SD
(0.8 SD), and femoral neck -2.7 SD (0.7 SD). After
1 year of denosumab treatment, scores increased signifi-
cantly at all three sites, reaching -2.7 SD (0.6 SD),
-2.1 SD (0.9 SD), and -2.4 SD (0.7 SD), respectively (all
p\ 0.0001 vs. baseline). No serious adverse drug reactions
were identified.
Conclusion Denosumab is usually prescribed in women
with PMO at high fracture risk. In the patients who were
persistent with treatment at 1 year, denosumab was well
tolerated and effective at increasing BMD T-scores at
several skeletal sites.
Key Points
This study reviewed the medical records of women
receiving denosumab for the treatment of
postmenopausal osteoporosis in Bulgaria.
The characteristics of the women suggest that they
were at high risk of fracture before they were
prescribed denosumab.
Denosumab increased bone mineral density after 1
year of treatment, which may help to reduce the risk
of fractures in this patient population.
1 Introduction
Osteoporosis is characterized by low bone mineral density
(BMD) and microarchitectural deterioration of bone tissue,
which leads to an increased risk of fracture [1]. It has been
estimated that 21% of women aged 50–84 years had
osteoporosis worldwide in 2010 and that approximately 22
million women in Europe were affected [2]. These findings
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are similar to those of the largest epidemiologic osteo-
porosis study in Bulgaria, in which 16.8% of women aged
50 years or older were found to have osteoporosis at the
femoral neck (FN) [3].
Fragility fractures are common in women over the age
of 50 years, and the risk of fracture correlates with
increasing age and decreasing BMD T-score [4, 5]. In
Bulgaria, the mean 10-year absolute fracture risk for
women with osteoporosis is reported to be 13.4% for major
fractures and 2.8% for hip fractures [3]. The risk of major
fractures was 8.8% in patients aged 50–59 years versus
19.6% in those aged 70 years and over, while the risk of
hip fractures in these age groups was 1.0 and 6.5%,
respectively. Over one-fifth (23.3%) of women reported
previous low-trauma fractures, including those affecting
the wrist (9.1% of low-trauma fractures), hip (1.9%), and
vertebrae (2.3%) [3]. Indeed, Svedbom et al. estimated that
in the 1.6 million women aged 50 years or older in Bul-
garia, 21,476 fractures might have occurred in 2010 [6].
However, data from the UK and Australia suggest that up
to one-half of all vertebral fractures may go unrecognized
[7, 8].
It has been estimated that, in Bulgaria in 2010, 7197
quality-adjusted life-years were lost in women aged over
50 years owing to osteoporotic fractures [6] and that the
cost burden of osteoporosis was €42 million [6]. Overall,
hip fractures were estimated to be the most expensive type
of fracture (€20 million), with the cost per fracture in 2010
estimated at €1826 [6].
Denosumab, a fully-human monoclonal antibody (IgG2)
against RANK ligand (RANKL), was approved in Europe
in 2010 for the treatment of osteoporosis in patients with an
increased risk of fractures [9, 10]. Denosumab binds
RANKL with high affinity and specificity, preventing
activation of its cognate receptor RANK that is expressed
on the surface of osteoclasts and osteoclast precursors.
Inhibition of signaling through the RANK receptor pre-
vents osteoclast maturation, activation and survival,
thereby decreasing bone resorption in cortical and trabec-
ular bone [9]. An in vivo animal study showed that inhi-
bition of bone resorption with denosumab improved the
structural strength of bone [11, 12]. Treatment with deno-
sumab has been associated with significant reductions in
fracture risk across a wide range of patient groups
[10, 13, 14]. Furthermore, long-term clinical trial follow-up
data from the phase III Fracture REduction Evaluation of
Denosumab in Osteoporosis every 6 months (FREEDOM)
extension study demonstrated that denosumab treatment
for up to 10 years was associated with a persistent reduc-
tion of bone turnover, continued increases in BMD, without
therapeutic plateau, and a low fracture incidence [15]. As a
consequence, Bulgarian guidelines recommend denosumab
[60-mg subcutaneous injection every 6 months (SC Q6M)]
as a first-line therapy to reduce the risk of vertebral, non-
vertebral, and hip fractures in women with postmenopausal
osteoporosis (PMO) [16].
It is of great interest to examine the profiles of patients
who receive denosumab in real-world clinical practice;
however, currently, such data are sparse. This study
describes the baseline characteristics and changes in BMD
T-scores among women with PMO who have received at
least two injections of denosumab in Bulgarian clinical
practice. This information may help to identify women




This retrospective, observational, multicenter chart review
planned to include 200 women from ten representative
osteoporosis practices in Bulgaria. The study protocol was
approved by a central regulatory agency ethics committee,
in accordance with the ethical principles of the Declaration
of Helsinki.
2.2 Participants
Women were considered eligible for inclusion if they were
aged 50 years or older, had a densitometric diagnosis of
PMO [BMD T-score B-2.5 standard deviations (SDs) at
one or more skeletal sites], had initiated denosumab
(60 mg SC Q6M) in or after October 2011, and had
received a second injection before the end of the study
period (August 2013). After enrollment, patients were
excluded if they had not received their second injection
within 7 months of the first; this time window (6 months
plus 1-month grace period) was used in accordance with
the coverage period of a denosumab injection, as stated in
the clinical practice guidelines for osteoporosis in Bulgaria
[16], and was in line with definitions of persistence that
have been used in previous studies of denosumab [17, 18].
Women were not eligible if they were currently or had ever
been enrolled in a clinical trial for denosumab, if they had
participated in any clinical trial in the 6 months before
their first denosumab injection, or if they were con-
traindicated for treatment with denosumab. All patients
provided informed consent to allow access to their relevant
medical records.
2.3 Study Sites and Data Collection
The study sites were selected on the basis of geographic
area, availability of electronic or paper medical records,
126 M. Boyanov et al.
and the number of women with osteoporosis treated with
denosumab. At each study site, the principal investigator
reviewed the medical records of postmenopausal women
initiating denosumab for osteoporosis in or after October
2011 who had received a second injection within 7 months
of their first injection and before the end of the study period
(August 2013). Up to a maximum number of eligible
women per site (which was proportional to the number of
women who met the inclusion criteria at each site and was
specified in the study contract) were randomly selected for
inclusion via a computerized system. Women enrolled into
the study were followed up from the date of their first
denosumab injection until the end of the study period, and
the data required as per the study protocol were then
transcribed onto an electronic case report form.
2.4 Study Outcomes
Data for all study variables were collected from the med-
ical records made by physicians when patients visited the
clinic to receive their denosumab injections. The variables
included physician-related, socio-demographic, condition-
related (including laboratory tests performed as part of
routine clinical practice), and health-related characteristics.
In addition, information was collected regarding deno-
sumab prescription and administration, procedures per-
taining to denosumab administration and osteoporosis,
concomitant medication use, adverse events (AEs), and
adverse drug reactions (ADRs) or serious ADRs.
2.5 BMD Measurement
Data on BMD at baseline and at 1 year after denosumab
initiation (as required for local reimbursement) were col-
lected for one or more of the following skeletal sites: lumbar
spine (LS) in the posterior–anterior position; total hip (TH);
and FN. To allow the mean change in a BMD T-score
between baseline and 1 year to be calculated, both mea-
surements had to have been taken at the same skeletal site and
using the same dual x-ray absorptiometry (DXA) instrument.
Across the study sites, the following DXA machine models
were used: Lunar Prodigy, Lunar DPX-IQ (manufactured by
General Electric Healthcare, Massachusetts, USA), Hologic
1500, Hologic 2000 and Hologic C (manufactured by
Hologic, Massachusetts, USA). Owing to the different
instruments used across the study sites, BMD T-scores were
used instead of absolute BMD values. T-scores are presented
as mean (SD) unless otherwise specified.
2.6 Statistical Analyses
The sample size of 200 women represents approximately
1% of the women with PMO in Bulgaria. Furthermore,
based on the assumption that a prevalence of 1% or more of
the population would have each of the patient-related
characteristics, the chances of observing at least one event
among a sample of 200 patients is 87%. Paired t tests were
used to compare BMD T-scores recorded at baseline with
those recorded after 1 year of treatment with denosumab.
The v2 test of independence was used to verify distribu-
tional independence of outcome variables and patient
groupings. A significance level of 0.05 was used.
The outcome variables LS, TH, and FN BMD T-scores
were analyzed according to the following patient cate-
gories: with/without previous fracture, exposed/not
exposed to prior PMO therapy, and age group. Age and
prior PMO therapy were analyzed according to whether
patients had a previous fracture or not. Continuous vari-
ables were summarized using mean and SD or 95% con-
fidence intervals (CIs); categorical values were
summarized as the number and proportion of women in
each category.
3 Results
3.1 Patient Characteristics at Baseline
A total of 228 women who met the eligibility criteria were
randomly selected for this chart review from 13 sites in
Bulgaria. Overall, 222 women were included in the anal-
yses and their baseline characteristics are presented in
Table 1. Of the six women excluded from the final anal-
yses, three had exceeded the recommended interval
between denosumab injections and three were excluded at
the request of their physician. The mean (SD) age at ini-
tiation of denosumab was 64.2 (8.5) years. Half of all
women were younger than 65 years, and 13.1% were aged
75 years or older. Approximately one-third (30.2%) of
women had comorbidities at baseline.
Approximately one-third (31.5%) of women had
received prior osteoporosis therapy at any time during their
history. The majority (56.3%) of women were not receiv-
ing dietary supplementation with calcium or vitamin D at
baseline (Table 1), and few women were receiving cal-
cium-only (5.9%) vitamin D-only (2.7%) supplements.
More than one-quarter (26.6%) of women reported a
previous fracture. Of those reporting a previous fracture,
11.9% of women reported two previous fractures. The most
common fracture type was vertebral (71.2% of women),
followed by hip (6.8%). Hospitalization as a result of an
osteoporotic fracture was reported for 15.3% of women
(Table 1).
Of those who reported a previous fracture, only half (29/
59; 49.2%) had received previous osteoporosis therapy. A
v2 test of independence found a statistically significant
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Table 1 Characteristics of
Bulgarian women with PMO at
denosumab initiation
Characteristic Study population (n = 222)
Age at menopause, years, mean (SD)a 48.1 (4.0)
Time since PMO diagnosis, years, mean (SD) 1.8 (4.6)
Body mass index, n (%)
B25 kg/m2 122 (55.0)
[25 kg/m2 77 (34.7)
No data 23 (10.4)
Current smoker, n (%)
Yes 24 (10.8)
No 192 (86.5)
Secondary osteoporosis, n (%)
Yes 6 (2.7)
No 216 (97.3)
Age at denosumab initiation, years, mean (SD) 64.2 (8.5)
Age at denosumab initiation, n (%)
\65 years 110 (49.5)
65–74 years 83 (37.4)
C75 years 29 (13.1)
Comorbidities, n (%)b 67 (30.2)
Cardiovascular disease 37 (16.7)
Metabolic disorders 15 (6.8)
Gastrointestinal disorders 13 (5.9)
Osteoarthritis 6 (2.7)
Respiratory disorders 4 (1.8)
Central nervous system disorders 3 (1.4)
Rheumatoid arthritis 3 (1.4)
Height loss since maximal height, n (%)
Yes 110 (49.5)
No 112 (50.5)
Height loss, cm, mean (SD) 3.2 (1.9)
Family history of osteoporotic fracture, n (%)
Yes 43 (19.4)
No 179 (80.6)
Prior PMO therapy, n (%)
Yes 70 (31.5)
No 152 (68.5)
Calcium and/or vitamin D supplementation, n (%)
Both 78 (35.1)
Calcium only 13 (5.9)
Vitamin D only 6 (2.7)
None 125 (56.3)
Previous fracture, n (%)
Yes 59 (26.6)
1 fracturec 52 (88.1)





Previous hospitalization for osteoporotic fracturec
Hospitalization 9 (15.3)
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relationship between age group and previous fracture
(p\ 0.0001). Previous fractures were more prevalent in
older women: 62.1% of women aged 75 years or older had
experienced a previous fracture compared with 10.0% of
those who were younger than 65 years (Table 2).
The indications given for prescribing denosumab are
listed in Table 3. Most women (98.6%) were prescribed
denosumab because they had a BMD T-score of less than
-2.5 SD. The next most common reasons for initiating
denosumab were history of osteoporotic fracture (22.1%)
and multiple risk factors for fracture (20.3%). Some
women (5.0%) were prescribed denosumab because they
were intolerant to other therapies. More than one reason
could be given per patient.
3.2 Changes in BMD T-Scores at 1 Year
At baseline, mean (SD) BMD T-scores were -3.2 SD
(0.6 SD) at the LS, -2.3 SD (0.8 SD) at the TH, and
-2.7 SD (0.7 SD) at the FN (Fig. 1). After 1 year of
denosumab treatment, mean BMD T-scores had increased
significantly to -2.7 SD (0.6 SD), -2.1 SD (0.9 SD), and
-2.4 SD (0.7 SD) at the LS, TH, and FN, respectively
(Fig. 1). Increases in BMD T-scores were calculated for the
women who met the criteria of having baseline and 1-year
measurements performed at the same skeletal site and
using the same DXA unit. Mean (95% CI) increases in
BMD T-score were 0.47 SD (0.42–0.53; n = 183) at the
LS, 0.27 SD (0.18–0.35; n = 64) at the TH, and 0.33 SD
(0.26–0.39; n = 121) at the FN (all p\ 0.0001, Fig. 1).
3.3 Safety
No new fractures or serious falls were recorded in the year
following initiation of denosumab. Furthermore, no AEs,
serious AEs, or ADRs related to the use of denosumab
were identified from the review of the medical records.
4 Discussion
In this retrospective, real-world chart review of women
with PMO in Bulgaria receiving at least two injections of
denosumab, the drug was usually prescribed to those at
high fracture risk. In the patients who were persistent with
treatment at 1 year, denosumab was well tolerated and was
effective in increasing BMD T-scores at several skeletal
sites.
The baseline characteristics of the enrolled Bulgarian
women, such as age and time since menopause, were
generally similar to those of patient populations in other
studies [10, 19, 20]. However, baseline BMD T-scores
were lower, indicating that the women were at a high risk
of fracture [4, 5, 21, 22]. The low T-scores could reflect the
local reimbursement criterion for denosumab in Bulgaria,
which stipulates that the cost for denosumab 60 mg SC
Q6M is partially reimbursed for those with a BMD T-score
of -2.5 SD or less at one or more skeletal site.
The mean changes in BMD T-scores observed in our
study were consistent with response to treatment and are
similar to those reported in other studies of women with
Table 1 Continued Characteristic Study population (n = 222)
Surgery 8 (13.6)
PMO postmenopausal osteoporosis, SD standard deviation
a Data not available for 20 patients (n = 202)
b Comorbidities that were present in C1% of patients overall are presented
c Percentages calculated from number of patients who had experienced a previous fracture
Table 2 Previous fracture by




Previous fracture Age groupa
\65 years (n = 110) 65–74 years (n = 83) C75 years (n = 29)
Yes (n = 59) 11 (10.0) 30 (36.1) 18 (62.1)
No (n = 163) 99 (90.0) 53 (63.9) 11 (37.9)
Data shown are number of patients (%). Percentages are calculated from the total number of patients in
each age group
a v2 test of independence demonstrated a significant relationship between age group and previous fracture
(v2 = 38.1051; p\ 0.0001)
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PMO who received treatment with denosumab. The bene-
ficial effect of denosumab on BMD was also observed in
another study over longer follow-up periods, with sustained
improvements in BMD at several skeletal sites: cumulative
8-year increases of 18.4% at the LS and 8.3% at the TH
were reported [23].
It has been reported for the year 2010 that only 5% of
the 240,000 women in Bulgaria eligible for treatment for
PMO received it [6]. A similar care gap has been reported
in other countries worldwide [24–28]. In our study, only
half of the women who had experienced previous fractures,
and were therefore at a high risk of subsequent fracture,
had received any prior treatment for PMO. This care gap
may reflect Bulgarian reimbursement requirements,
whereby women with PMO need to have annual DXA
scans to assess their BMD. However, the availability of
DXA scanning facilities is limited; there are only 34
scanners in Bulgaria, which is equivalent to approximately
five scanners per million people, and most scanners are
situated in large cities, which makes access difficult for less
mobile women [29]. Furthermore, the cost of PMO therapy
used to be reimbursed only up to 25% and women were
required to cover the remaining 75% [29]. Consequently,
many women would not have had access to PMO therapy,
including denosumab. In 2014, the reimbursement rate for
denosumab was increased to 50% of the total cost, which
may increase patient access to therapy.
The care gap is also evident in the low proportion of
women in our study who were receiving calcium or vitamin
D supplementation at baseline, despite local guidelines
advocating the use of these agents [29]. Calcium and
vitamin D supplements are cost-effective supplements to
PMO therapy [30] that have been shown to reduce bone
loss and the incidence of non-vertebral fractures [31]. The
low level of use of these agents is of concern and may be
due to patients’ fears regarding the development of kidney
stones or cardiovascular disease [32].
Denosumab was well tolerated by the women in this
chart review study. No AEs were reported during the
1-year follow-up period, although it should be noted that,
owing to the retrospective nature of the study, we could not
control for AEs not being recorded in patients’ medical
records. However, long-term data from the FREEDOM
extension study have shown that the incidence of AEs did
not increase over a treatment period of up to 9 years and
that the incidence of fractures remained low [33, 34]. Other
studies on the long-term safety of denosumab are ongoing.
There are some limitations to our study. No comparator
was used; therefore, the changes in BMD T-scores between
baseline and following denosumab initiation should be
interpreted with care. In addition, because different DXA
instruments were used at each study site, the use of abso-
lute BMD values would not have allowed accurate
grouping of data, so these data were not collected. Also, the
women had received at least a second injection of deno-
sumab within 7 months of the first injection and hence
were persistent with treatment at 1 year; consequently, the
results may not be generalizable to the entire population
receiving denosumab for PMO, because women may not be
persistent with denosumab therapy in real-world practice.
However, other studies have shown that rates of persistence
appear to be fairly high in routine clinical practice [17, 35].




BMD T-score\-2.5 SD 219 (98.6)
History of osteoporotic fracture 49 (22.1)
Multiple risk factors for fracture 45 (20.3)
Intolerant to other PMO therapies 11 (5.0)
Patient preference for convenience and
safety
2 (0.9)
Categories as reported to the Bulgarian National Health Insurance
Fund; more than one reason could be provided per patient. Data are
shown as n (%)
BMD bone mineral density, PMO postmenopausal osteoporosis, SD
standard deviation
Fig.1 BMD T-scores at baseline and after 1 year of denosumab
treatment in Bulgarian women with postmenopausal osteoporosis.
Data are shown as mean ± SD. Numbers within bars indicate
numbers of patients. Values below bars indicate mean change in
BMD T-score (95% confidence interval). Changes in BMD were
calculated only for the women who met the criteria of having baseline
and 1-year measurements performed at the same skeletal site and
using the same dual X-ray absorptiometry instrument (n = 183 for
lumbar spine, n = 64 for total hip, and n = 121 for femoral neck).
Paired t tests were used to compare BMD T-scores recorded at
baseline with those recorded at 1-year follow-up. BMD bone mineral
density, SD standard deviation
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Despite the limitations, this study provides insight into
the efficacy of denosumab in a persistent population of
women with PMO in Bulgaria.
5 Conclusion
This is the first real-world chart review study of women
with PMO receiving denosumab in Bulgaria. Among
women receiving two denosumab injections, BMD
T-scores increased significantly at several skeletal sites
after 1 year. No new fractures or new safety signals were
observed. Treatment with denosumab was effective in a
broad population of persistent patients for 1 year. Long-
term therapy with denosumab may help to reduce the
incidence of fracture and the subsequent burden on women
with PMO and on healthcare systems.
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